HER2-Positive Metastatic Breast Cancer — An Interview with Prof Dr Sibylle Loibl on First-Line and Maintenance Therapy

Featuring an interview with Prof Dr Sibylle Loibl, including the following topics:

Perspectives on overall survival gains achieved over the years for patients with metastatic breast cancer (mBC) (0:00)
Previous treatment and patient outcomes in the DESTINY-Breast09 trial of trastuzumab deruxtecan (T-DXd) with or without pertuzumab (5:35)
Role of endocrine therapy in the treatment of hormone receptor-positive, HER2-positive mBC (8:01)
Targeting the PI3K signaling pathway in HER2-positive mBC (11:08)
Contraindications for T-DXd; T-DXd-associated gastrointestinal toxicities and interstitial lung disease (13:53)
Optimal duration of and therapeutic partner for T-DXd as first-line maintenance therapy for patients with HER2-positive mBC (20:44)
Case: A woman in her early 40s with metastatic relapse of HER2-positive breast cancer 2 years after completing neoadjuvant and adjuvant therapy (26:54)
Role of exercise and weight control in the management of breast cancer; effect of pregnancy on the breast tumor immune environment (40:03)